US pharmacists "unaware" they dispense illegal drugs

3 September 2006

Medical Marketing Research, a North Carolina, USA-based market research consultancy specializing in health care research, has published survey results that indicate that as many as 91% of US pharmacists are unaware they dispense drugs that have not been approved by the US Food and Drug Administration.

The agency itself estimates that several thousand drugs are marketed illegally, without required FDA approval. The survey consisted of a nationwide, random sample of 500 US retail pharmacists who were questioned about their dispensing habits for pharmaceutical products. More information on unlicensed drugs can be obtained via the Internet from the FDA at www.fda.gov/cder/guidance/6911fnl.pdf. Survey information can be found on the Medical Marketing Research web site: www.mmrx.com.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight